Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery (NCT06762782) | The First Affiliated Hospital with Nanjing Medical University | 2025-02-01 |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (NCT05367687) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-01 |
Track Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation automatically
Every clearance here is in the API, with alerts when new ones post.